KCA
Search
- Page Path
- HOME > Search
Original Articles
- Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-line Platinum-based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)
- Inkeun Park, Shinkyo Yoon, Ilhwan Kim, Kwonoh Park, Suee Lee, Bhumsuk Keam, Joo-Hwan Park, Jin Young Kim, Yoon Ji Choi, Byeong Seok Sohn, Jae Lyun Lee
- Received October 16, 2024 Accepted December 26, 2024 Published online December 27, 2024
- DOI: https://doi.org/10.4143/crt.2024.1003 [Accepted]
-
Abstract
PDF - Purpose
Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
Materials and Methods
Eligible aUC patients who did not progress after 4–6 cycles of cisplatin or carboplatin-based chemotherapy were randomized 1:1 to receive maintenance pemetrexed (500 mg/m2 IV every 3 weeks, up to 16 cycles) or observation. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response rate, and safety.
Results
The trial was closed early due to slow accrual after avelumab approval. From October 2016 to December 2022, 97 patients were randomized to pemetrexed (n=49) or observation (n=48). The median age was 69 years (range: 43–90) and 66 (range33–82), respectively, with 63% and 73% of patients being male, respectively. The median PFS was 6.0 months (95% CI, 3.4–8.5) with pemetrexed versus 2.3 months (1.8–2.7) with observation (p=0.044, HR 0.64; 95% CI, 0.41–0.99). The median OS was 18.1 months (95% CI, 6.9–29.4) for pemetrexed and 17.9 months (16.1–19.7) for observation (p=0.913, HR 1.03; 95% CI, 0.61–1.73). Common adverse events in the pemetrexed group included anemia (30%), fatigue (18%), and neutropenia (12%), primarily grade 1 or 2.
Conclusion
The PREMIER trial showed that switch maintenance pemetrexed significantly prolonged PFS in aUC patients post-1L platinum-based chemotherapy, with a favorable safety profile. Further studies on combination maintenance therapies are warranted.
- 499 View
- 44 Download
- Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
- Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
- Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019
- DOI: https://doi.org/10.4143/crt.2019.292
-
Abstract
PDF
PubReader
ePub - Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required. -
Citations
Citations to this article as recorded by
- Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
The Oncologist.2025;[Epub] CrossRef - From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing, Fandou Kong
Journal of Ovarian Research.2024;[Epub] CrossRef - SOX17 expression in ovarian clear cell carcinoma
Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
Journal of Ovarian Research.2024;[Epub] CrossRef - Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef - Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
Li Shuqing, Zhu Zhiling
Cancer Medicine.2023; 12(6): 6668. CrossRef - Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
Current Medical Research and Opinion.2023; 39(6): 901. CrossRef - The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
Yuan Zhuang, Hua Yang
Cancer Control.2023;[Epub] CrossRef - Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
Satoe Fujiwara
Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef - Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
Journal of Gynecologic Oncology.2023;[Epub] CrossRef - Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
Yang Gao, Wei Ding, Pengpeng Qu
Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef - A clearer view on ovarian clear cell carcinoma
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
Acta Clinica Belgica.2022; 77(4): 792. CrossRef - Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef - Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
Peng Chen, Chi-Yuan Zhang
Frontiers in Oncology.2022;[Epub] CrossRef - Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
Medicine.2022; 101(37): e30666. CrossRef - Clear cell carcinoma of the ovary: a clinical and molecular perspective
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef - Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
BMC Cancer.2021;[Epub] CrossRef - The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef - Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
Qian Chen, Shu Wang, Jing-He Lang
Journal of Ovarian Research.2020;[Epub] CrossRef
- Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
- 9,263 View
- 427 Download
- 23 Web of Science
- 18 Crossref
- BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
- Sung-Bae Kim, In-Gu Do, Janice Tsang, Tae-You Kim, Yoon-Sim Yap, Gerardo Cornelio, Gyungyub Gong, Soonmyung Paik, Suee Lee, Ting-Ying Ng, Sarah Park, Ho-Suk Oh, Joanne Chiu, Joohyuk Sohn, Moonhee Lee, Young-Jin Choi, Eun Mi Lee, Kyong-Hwa Park, Christos Nathaniel, Jungsil Ro
- Cancer Res Treat. 2019;51(4):1527-1539. Published online June 4, 2019
- DOI: https://doi.org/10.4143/crt.2018.598
-
Abstract
PDFPubReaderePub
- Purpose
BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients with HER2+ advanced breast cancer treated with lapatinib and other HER2-targeted agents. Materials and Methods Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, overall survival on lapatinib, correlation between biomarker status and PFS for any previous trastuzumab-based treatment, and conversion/conservation rates of the biomarker status between tissue samples collected at primary diagnosis and at recurrence/metastasis. Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored.
Results
p95HER2, PTEN deletion/downregulation, and PIK3CA mutation did not demonstrate any significant co-occurrence pattern and were not predictive of clinical outcomes on either lapatinib-based treatment or any previous trastuzumab-based therapy in the metastatic setting. Proportions of tumors positive for p95HER2 expression, PIK3CA mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2%, and 56.2%, respectively. Despite limited availability of paired samples, biomarker status patterns were conserved in most samples. HER2 mRNA levels were not predictive of PFS on lapatinib.
Conclusion
The prevalence of p95HER2 expression, PIK3CA mutation, and PTEN deletion/downregulation at primary diagnosis were similar to previous reports. Importantly, no difference was observed in clinical outcome based on the status of these biomarkers, consistent with reports from other studies. -
Citations
Citations to this article as recorded by- PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
Cancer Research and Treatment.2023; 55(2): 531. CrossRef - Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
Justus Rosin, Ella Svegrup, Antonios Valachis, Ioannis Zerdes
Breast Cancer Research and Treatment.2023; 201(2): 161. CrossRef - Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
Haizhu Chen, Xingbin Hu, Daquan Wang, Ying Wang, Yunfang Yu, Herui Yao
Translational Oncology.2023; 37: 101738. CrossRef - Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations
Jessica W. Chen, Karthikeyan Murugesan, Justin Y. Newberg, Ethan S. Sokol, Heidi M. Savage, Thomas J. Stout, Sophia L. Maund, Katherine E. Hutchinson
JCO Precision Oncology.2022;[Epub] CrossRef - Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Ugo Testa, Germana Castelli, Elvira Pelosi
Medical Sciences.2020; 8(1): 18. CrossRef
- PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
- 8,636 View
- 194 Download
- 4 Web of Science
- 5 Crossref
- Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
- In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro
- Cancer Res Treat. 2019;51(1):43-52. Published online February 14, 2018
- DOI: https://doi.org/10.4143/crt.2017.562
-
Abstract
PDFPubReaderePub
- Purpose
We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC).
Materials and Methods
A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2 twice a day, days 1-14) every 3 weeks. The primary endpoint was PFS.
Results
There was no significant difference in PFS between the combination and monotherapy arm (median, 6.4 months vs. 4.7 months; hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.63 to 1.11; p=0.84). In patients with triple-negative breast cancer (TNBC, n=90), the combination significantly improved PFS (median, 4.7 months vs. 2.5 months; HR, 0.58; 95% CI, 0.37 to 0.91; p=0.02). Objective response rate was numerically higher in the combination arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30). Overall survival did not differ between arms (median, 20.4 months vs. 24.0 months; p=0.63). While grade 3 or 4 neutropenia was more common in the combination arm (39.6% vs 9.0%), hand-foot syndrome was more often observed in capecitabine arm. Quality of life measurements in global health status was similar. However, patients in the combination arm showed significantly worse symptom scales especially in nausea/vomiting and diarrhea.
Conclusion
Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of the two groups differed but were manageable. The role of added irinotecan in patients with TNBC remains to be elucidated. -
Citations
Citations to this article as recorded by- The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef - Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence
José Ángel García-Saenz, Álvaro Rodríguez-Lescure, Josefina Cruz, Joan Albanell, Emilio Alba, Antonio Llombart
Targeted Oncology.2025; 20(2): 191. CrossRef - Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer
Cui-Cui Liu, Lie Chen, Yu-Wen Cai, Yu-Fei Chen, Yi-Ming Liu, Yu-Jie Zhou, Zhi-Ming Shao, Ke-Da Yu
Cell Reports Medicine.2024; 5(2): 101396. CrossRef - Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients
Weili Xiong, Ting Xu, Xiao Liu, Lili Zhang, Yuan Yuan
Cancer.2024; 130(S8): 1488. CrossRef - Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Mengqian Ni, Lijia Zhou, Yongkui Lu, Dachuan Guo, Xiuyue Li, Lixia Li, Lidong Zhang, Meiting Chen, Lulu Zhang, Fei Xu, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Anli Yang, Xin An
BMC Cancer.2024;[Epub] CrossRef - Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
npj Breast Cancer.2024;[Epub] CrossRef - A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer
Tingting Tang, Naiyu Liu, Lingjuan Wang, Kaiyue Zuo, Xinjie Zhu
ChemBioChem.2024;[Epub] CrossRef - Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy
Antonello Pinto, Chiara Guarini, Marianna Giampaglia, Valeria Sanna, Assunta Melaccio, Laura Lanotte, Anna Natalizia Santoro, Francesca Pini, Antonio Cusmai, Francesco Giuliani, Gennaro Gadaleta-Caldarola, Palma Fedele
Pharmaceutics.2024; 16(9): 1146. CrossRef - Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi-Sakita, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Danjie Zhang, Yuki Iwahori, Dianna Gary, Danh Huyn
International Journal of Clinical Oncology.2024; 29(11): 1684. CrossRef - A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments
Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
International Journal of Cancer.2023; 152(10): 2134. CrossRef - Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review
Salvatore Greco, Nicolò Fabbri, Riccardo Spaggiari, Alfredo De Giorgi, Fabio Fabbian, Antonio Giovine
Biomedicines.2023; 11(6): 1772. CrossRef - Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
Jiao Xie, SiNi Li, YaMin Li, JianHe Li
BMC Health Services Research.2023;[Epub] CrossRef - Triple negative breast cancer: second and successive lines of treatment
Fernando Henao Carrasco, Sara Leal Sánchez
Revisiones en Cáncer.2023;[Epub] CrossRef - TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Rebecca A Dent, David W Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A Traina, Petra Vukovic, Darlington Mapiye, Micah J Maxwell, Peter Schmid, Javier Cortés
Future Oncology.2023; 19(35): 2349. CrossRef - An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
Shao-Xian Cheng, Qiu-Chi Chen, Guo-He Lin, Yan-Hong Han, Bi-Cheng Wang, Yi Dai, Yan-Xia Zhao
Medicine.2023; 102(30): e34486. CrossRef - Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
Wensheng Liu, Qiong Du, Zihan Guo, Xuan Ye, Jiyong Liu
Frontiers in Pharmacology.2023;[Epub] CrossRef - Effects of Sacituzumab on Breast Cancer: Target Therapy
Elina Armani Khatibi, Tooba Gholikhani, Balam Jimenez Brito, Nastaran Farshbaf Moghimi
Biomedical Research Bulletin.2023; 1(4): 141. CrossRef - The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC
Chris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, Simona Borstnar, Luc Dirix, Petra Tesarova, Constanta Timcheva, Lyudmila Zhukova, Xavier Pivot
Clinical Breast Cancer.2022; 22(3): 223. CrossRef - Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future
Fatima Cardoso, David Cella, Galina Velikova, Victoria Harmer, Eva Schumacher-Wulf, Julie Rihani, Ana Casas, Nadia Harbeck
Cancer Treatment Reviews.2022; 102: 102321. CrossRef - Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Yi Xiao, Ding Ma, Yun-Song Yang, Fan Yang, Jia-Han Ding, Yue Gong, Lin Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Yu, Qing Zhang, François Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Zhi-Ming Shao, Yi-Zhou Jiang
Cell Research.2022; 32(5): 477. CrossRef - Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
F. Miglietta, M. Bottosso, G. Griguolo, M.V. Dieci, V. Guarneri
ESMO Open.2022; 7(2): 100409. CrossRef - Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
JAMA Oncology.2022; 8(6): 879. CrossRef - Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, S
Breast Cancer Research and Treatment.2022; 195(2): 127. CrossRef - Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Picc
npj Breast Cancer.2022;[Epub] CrossRef - Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo,
npj Breast Cancer.2022;[Epub] CrossRef - Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
Dou-Dou Li, Zhong-hua Tao, Bi-Yun Wang, Lei-Ping Wang, Jun Cao, Xi-Chun Hu, Jian Zhang
npj Breast Cancer.2022;[Epub] CrossRef - Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
Jiawei Shou, Fan Mo, Shanshan Zhang, Lantian Lu, Ning Han, Liang Liu, Min Qiu, Hongseng Li, Weidong Han, Dongying Ma, Xiaojie Guo, Qianpeng Guo, Qinxue Huang, Xiaomeng Zhang, Shengli Ye, Hongming Pan, Shuqing Chen, Yong Fang
Frontiers in Immunology.2022;[Epub] CrossRef - A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun’e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junla
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef - Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
Jasgit C. Sachdev, Pamela Munster, Donald W. Northfelt, Hyo Sook Han, Cynthia Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey Anders
Breast Cancer Research and Treatment.2021; 185(3): 759. CrossRef - Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar D. Sardesai, Kevin Kalinsky, Amelia B. Zelnak, Robert Weaver, Tiffany Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab,
New England Journal of Medicine.2021; 384(16): 1529. CrossRef - Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset H
npj Breast Cancer.2021;[Epub] CrossRef - Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report
Angelats L, Estival A, Martinez-Cardús A, Musulen E, Margelí M
Current Problems in Cancer: Case Reports.2021; : 100097. CrossRef - A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo
Frontiers in Oncology.2021;[Epub] CrossRef - Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef - High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
Inken Flörkemeier, Tamara N. Steinhauer, Nina Hedemann, Jörg Paul Weimer, Christoph Rogmans, Marion T. van Mackelenbergh, Nicolai Maass, Bernd Clement, Dirk O. Bauerschlag
Cancers.2021; 14(1): 2. CrossRef - Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
Jennifer A. Weiss, Andrew Nicklawsky, Jodi A. Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, Sarah L. Davis, Stephen Leong, Sue Gail Eckhardt, Jennifer R. Diamond
Cancer Medicine.2020; 9(23): 8801. CrossRef - Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
Vito Lorusso, Agnese Latorre, Francesco Giotta, Ozkan Kanat
Journal of Oncology.2020; 2020: 1. CrossRef - Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan
New England Journal of Medicine.2019; 380(8): 741. CrossRef - An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen
Cancer Chemotherapy and Pharmacology.2019; 84(2): 441. CrossRef - Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy
Burak Yasin Aktas, Gurkan Guner, Deniz Can Guven, Cagatay Arslan, Omer Dizdar
Expert Review of Anticancer Therapy.2019; 19(7): 589. CrossRef - Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Jennifer Weiss, Ashley Glode, Wells A. Messersmith, Jennifer Diamond
Expert Review of Anticancer Therapy.2019; 19(8): 673. CrossRef - The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
I V Kolyadina, I V Poddubnaya
Journal of Modern Oncology.2018; 20(3): 26. CrossRef
- The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
- 10,939 View
- 454 Download
- 38 Web of Science
- 42 Crossref
- Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
- Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim
- Cancer Res Treat. 2018;50(2):488-494. Published online May 22, 2017
- DOI: https://doi.org/10.4143/crt.2016.584
-
Abstract
PDF
Supplementary MaterialPubReaderePub - Purpose
The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC.
Materials and Methods
Patientswith locally advanced or metastatic nccRCC, exceptfor collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cyclewas defined as 4weeks and tumorresponsewas evaluated every two cycles. The primary objective was overall response rate (ORR).
Results
A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment-related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay.
Conclusion
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC. -
Citations
Citations to this article as recorded by- Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
Balqees Ara, Anum Babar, Durkho Atif, Bushra Ghafoor, Mustafa Shah, Syed Maaz Abdullah, Danish Safi, Amir Kamran
Journal of Oncology Pharmacy Practice.2025; 31(1): 128. CrossRef - Liver metastasis from a chromophobe renal cell carcinoma 18 years after initial diagnosis: a case report
Alexandra Ökrösi, Lothar Ponhold, Simon Turba, Melitta Kitzwögerer, Gertraud Heinz
Journal of Medical Case Reports.2025;[Epub] CrossRef - Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
International Journal of Cancer.2024; 154(6): 947. CrossRef - Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andra
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef - Papillary Renal Cell Carcinoma: Current Evidence and Future Directions
Albert Jang, Charbel S. Hobeika, Shilpa Gupta
Kidney Cancer.2024; 8(1): 61. CrossRef - Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Hasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova, Tugay Avci, Halil Göksel Güzel, Caner Kapar, Mehmet Uzun, Perihan Perkin, Fahri Akgül, Saadet Sim Yildirim, Seda Sali, Anil Yildiz, Seher Nazli Kazaz, Engin Hendem, Murat Arcagok, G
Journal of Chemotherapy.2024; : 1. CrossRef - Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective
Gaetano Pezzicoli, Vittoria Musci, Federica Ciciriello, Francesco Salonne, Paola Cafforio, Nicoletta Lionetti, Anna Ragno, Mimma Rizzo
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef - Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
Frontiers in Oncology.2024;[Epub] CrossRef - Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma
Floriane Izarn, Benoît Allignet, Romane Gille, Helen Boyle, Eve-Marie Neidhardt, Sylvie Négrier, Aude Fléchon
Clinical Genitourinary Cancer.2023; 21(2): e35. CrossRef - SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama, Cristina Suárez Rodriguez, José Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo Díaz, Julio Lambea Sorrosal, Aránzazu González-del-Alba
Clinical and Translational Oncology.2023; 25(9): 2732. CrossRef - Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğl
Urologia Internationalis.2023; 107(6): 595. CrossRef - The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database
Tomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, Kazuyuki Numakura, Yumina Muto, Renpei Kato, Takahiro Kojima, Yoshihide Kawasaki, Kento Morozumi, Shuya Kandori, Sadafumi Kawamura, Hiroyuki Nishiyama, Akihiro Ito, Tomonori Habuchi, Wataru Obara, Chikara Oh
Cancer Medicine.2023; 12(22): 20677. CrossRef - Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Pay
Journal of the National Comprehensive Cancer Network.2022; 20(1): 71. CrossRef - Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma
Jason R. Brown, Adam Calaway, Erik Castle, Jorge Garcia, Pedro C. Barata
Kidney Cancer.2022; 6(1): 53. CrossRef - Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches
Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer, Massoud Vosough
International Journal of Translational Medicine.2022; 2(4): 555. CrossRef - Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds
Panagiotis Zoumpourlis, Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel
Clinical Genitourinary Cancer.2021; 19(2): 103. CrossRef - Comprehensive review of chromophobe renal cell carcinoma
Rohan Garje, Dean Elhag, Hesham A Yasin, Luna Acharya, Daniel Vaena, Laila Dahmoush
Critical Reviews in Oncology/Hematology.2021; 160: 103287. CrossRef - A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
Chelsea K. Osterman, Tracy L. Rose
Kidney Cancer.2020; 4(1): 15. CrossRef - Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report
Ivana Puliafito, Alessio Russo, Dorotea Sciacca, Caterina Puglisi, Dario Giuffrida
Journal of Medical Case Reports.2020;[Epub] CrossRef - On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
American Society of Clinical Oncology Educational Book.2020; (40): 418. CrossRef - Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef - Management of Metastatic Renal Cell Carcinoma with Variant Histologies
Ronan Flippot, Vijay Damarla, Bradley A. McGregor
Urologic Clinics of North America.2020; 47(3): 319. CrossRef - Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors
Silvia Salerno, Elisabetta Barresi, Aída Nelly García-Argáez, Sabrina Taliani, Francesca Simorini, Giorgio Amendola, Stefano Tomassi, Sandro Cosconati, Ettore Novellino, Federico Da Settimo, Anna Maria Marini, Lisa Dalla Via
ACS Medicinal Chemistry Letters.2019; 10(4): 457. CrossRef - Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tri
The Lancet Oncology.2019; 20(4): 581. CrossRef - Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas
Keiichi Ito
International Journal of Urology.2019; 26(9): 868. CrossRef - Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee
BMC Urology.2019;[Epub] CrossRef - Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1578. CrossRef - The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
Gregory T. Sneed, Sukdong Lee, Jamie N. Brown, Julia M. Hammond
Clinical Genitourinary Cancer.2019; 17(6): 419. CrossRef - A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
Inkeun Park, Se Hoon Lee, Jae Lyun Lee
Clinical Genitourinary Cancer.2018; 16(5): e997. CrossRef - Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan
Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayaka
Clinical Genitourinary Cancer.2018; 16(6): e1201. CrossRef
- Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
- 11,060 View
- 494 Download
- 38 Web of Science
- 30 Crossref
- Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
- Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung
- Cancer Res Treat. 2017;49(2):423-429. Published online August 3, 2016
- DOI: https://doi.org/10.4143/crt.2016.191
-
Abstract
PDFPubReaderePub
- Purpose
Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC),who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials.
Materials and Methods
In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease.
Results
A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively.
Conclusion
This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC. -
Citations
Citations to this article as recorded by- Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
Yu-Ju Lin, Chun-Nan Kuo, Yu Ko
The Breast.2021; 57: 18. CrossRef - Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
Pei-Hsin Chen, Dah-Cherng Yeh, Heng-Hsin Tung, Chin-Yao Lin
Medicine.2021; 100(47): e27859. CrossRef - Multifarious targets beyond microtubules—role of eribulin in cancer therapy
Priya Seshadri, Barnali Deb, Prashant Kumar
Frontiers in Bioscience-Scholar.2021;[Epub] CrossRef - A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh, Geumhee Gwak, Tae Hyun Kim, Young Bum Yoo, Hyun-Ah Kim, Min Young Kim, Ju Yeon Kim, Joon Jeong
The Breast.2020; 54: 121. CrossRef - Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
Kun-Ming Rau, Fu Ou-Yang, Ta-Chung Chao, Yao-Lung Kuo, Tsui-Fen Cheng, Tsu-Yi Chao, Dar-Ren Chen, Yen-Dun Tzeng, Being-Whey Wang, Chun-Yu Liu, Ming-Hung Hu, Yin-Che Lu, Wei-Jen Ou, Chin-Ho Kuo, Chieh-Han Chuang, Jung-Yu Kan, Fang-Ming Chen, Ming-Feng Hou
Breast Cancer Research and Treatment.2018; 170(3): 583. CrossRef - Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2018; 128: 110. CrossRef - Angiomodulators in cancer therapy: New perspectives
Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Büsselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak
Biomedicine & Pharmacotherapy.2017; 89: 578. CrossRef - Eribulin in Advanced Breast Cancer: Safety, Efficacy and New Perspectives
Ornella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua, Marco C Merlano
Future Oncology.2017; 13(30): 2759. CrossRef - Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
Ling Peng, Yun Hong, Xianghua Ye, Peng Shi, Junyan Zhang, Yina Wang, Qiong Zhao
Oncotarget.2017; 8(67): 112076. CrossRef
- Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
- 11,993 View
- 333 Download
- 6 Web of Science
- 9 Crossref
- Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer
- Kyung A Kwon, Jeanho Yun, Sung Yong Oh, Bong-Gun Seo, Suee Lee, Ji-Hyun Lee, Sung-Hyun Kim, Hong Jo Choi, Mee Sook Roh, Hyo-Jin Kim
- Cancer Res Treat. 2016;48(1):198-207. Published online June 23, 2015
- DOI: https://doi.org/10.4143/crt.2015.024
-
Abstract
PDFPubReaderePub
- Purpose
The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. Thyroid hormone receptor-associated proteins 220 (TRAP220) is an essential component of the TRAP/Mediator complex. The objective of this study was to clarify whether PPARγ or TRAP220 are significant prognostic markers in resectable colorectal cancer (CRC).
Materials and Methods
A total of 399 patients who underwent curative resection for CRC were enrolled. We investigated the presence of PPARγ and TARP220 in CRC tissues and adjacent normal tissues by immunohistochemistry. Correlation between the expression of these factors and clinicopathologic features and survival was investigated.
Results
Median age of the patients was 63 years (range, 22 to 87 years), and median follow-up duration 61.1 months (range, 2 to 114 months). PPARγ and TRAP220 expression showed significant correlation with depth of invasion (p=0.013 and p=0.001, respectively). Expression of TRAP220 also showed association with lymph node metastasis and TNM stage (p=0.001). Compared with patients with TRAP220 negative tumors, patients with TRAP220 positive tumors had longer 5-year disease-free survival (DFS) tendency (p=0.051). Patients who were PPARγ positive combined with TRAP220 positive had a better 5-year DFS (64.8% vs. 79.3%, p=0.013). In multivariate analysis expression of both PPARγ and TRAP220 significantly affected DFS (hazard ratio, 0.620; 95% confidence interval, 0.379 to 0.997; p=0.048).
Conclusion
TRAP220 may be a valuable marker for nodal metastasis and TNM stage. Tumor co-expression of PPARγ and TRAP220 represents a biomarker for good prognosis in CRC patients. -
Citations
Citations to this article as recorded by- Expression of Peroxisome Proliferator-Activated Receptor γ in Human Colorectal Carcinoma and Its Correlation with Clinicopathological Characteristics
Deepsikha Dharamsaktu, Jyotsna Naresh Bharti, Poonam Elhence, Meenakshi Rao, Jeewan Ram Vishnoi, Subash Chandra Soni, Neeti Rustagi
Indian Journal of Surgical Oncology.2024;[Epub] CrossRef - The Role of Fatty Acid Metabolism, the Related Potential Biomarkers, and Targeted Therapeutic Strategies in Gastrointestinal Cancers
Ruixi Xie, Ying Luo, Bowen Bao, Xinshu Wu, Jia Guo, Jin Wang, Xiujuan Qu, Xiaofang Che, Chunlei Zheng
Drug Development Research.2024;[Epub] CrossRef - A review on the molecular mechanisms, the therapeutic treatment including the potential of herbs and natural products, and target prediction of obesity-associated colorectal cancer
Huihai Yang, Grace Gar Lee Yue, Ping Chung Leung, Chun Kwok Wong, Clara Bik San Lau
Pharmacological Research.2022; 175: 106031. CrossRef - UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress Control
Angèle Luby, Marie-Clotilde Alves-Guerra
International Journal of Molecular Sciences.2022; 23(23): 15077. CrossRef - Lycopene supplementation regulates the gene expression profile and fat metabolism of breeding hens
Hanchen Tian, Guangbin Liu, Yongqing Guo, Yaokun Li, Ming Deng, Dewu Liu, Baoli Sun
Journal of Animal Physiology and Animal Nutrition.2020; 104(3): 936. CrossRef - Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ
Jing Zhou, Zhanzhao Liu, Lingjing Zhang, Xiao Hu, Zhihua Wang, Hong Ni, Yue Wang, Junfang Qin
Cancer Research and Treatment.2020; 52(3): 830. CrossRef - Checkpoint-dependent phosphorylation of Med1/TRAP220 in response to DNA damage
Hyun-Ju Kim, Jeanho Yun
Acta Biochimica et Biophysica Sinica.2017; 49(6): 496. CrossRef - Expression and role of nuclear receptor coregulators in colorectal cancer
Mouna Triki, Marion Lapierre, Vincent Cavailles, Raja Mokdad-Gargouri
World Journal of Gastroenterology.2017; 23(25): 4480. CrossRef
- Expression of Peroxisome Proliferator-Activated Receptor γ in Human Colorectal Carcinoma and Its Correlation with Clinicopathological Characteristics
- 11,623 View
- 64 Download
- 8 Web of Science
- 8 Crossref
- A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
- Dong Hyun Lee, Sung Yong Oh, Yu Rim Lee, Seok Jae Huh, Hyun Hwa Yoon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Young Kim, Hyo-Jin Kim, Hyuk-Chan Kwon
- Cancer Res Treat. 2011;43(4):225-230. Published online December 27, 2011
- DOI: https://doi.org/10.4143/crt.2011.43.4.225
-
Abstract
PDFPubReaderePub
- PURPOSE
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin, and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin.
MATERIALS AND METHODS
CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2 on day 1, leucovorin 20 mg/m2 followed by 5-fluorouracil (5-FU) via a 400 mg/m2 bolus and a 22 hours continuous infusion of 600 mg/m2 5-FU on days 1-2 at 2-week intervals.
RESULTS
Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) received previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%) were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete response and five patients (14.3%) showed partial response. The median time to progression was 4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5 months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death. Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic antigen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic antigen level (37.2 months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs. 6.8 months, p=0.040) showed better overall survival.
CONCLUSION
The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC. -
Citations
Citations to this article as recorded by- Results of complete cytoreductive strategy in patients with peritoneal metastases of colorectal origin with or without extraperitoneal metastases: A bicentric analysis
Isabelle Sourrouille, Clément Pastier, Maximilliano Gelli, Léonor Benhaïm, Pierre Cattan, Michel Ducreux, Thomas Aparicio, Diane Goéré
European Journal of Surgical Oncology.2025; 51(1): 108788. CrossRef - Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis
Udit Nindra, Adel Shahnam, Kate L. Mahon
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 7. CrossRef - Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial
Gabriel Glockzin, Florian Zeman, Roland S. Croner, Alfred Königsrainer, Jörg Pelz, Michael A. Ströhlein, Beate Rau, Dirk Arnold, Michael Koller, Hans J. Schlitt, Pompiliu Piso
Clinical Colorectal Cancer.2018; 17(4): 285. CrossRef - Treatment of peritoneal metastases from small bowel adenocarcinoma
Koen P. Rovers, Eelco de Bree, Yutaka Yonemura, Ignace H. de Hingh
International Journal of Hyperthermia.2017; 33(5): 571. CrossRef - Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis
T.A. Bin Traiki, O.M. Fisher, S.J. Valle, R.N. Parikh, M.A. Kozman, D. Glenn, M. Power, W. Liauw, N.A. Alzahrani, D.L. Morris
European Journal of Surgical Oncology (EJSO).2017; 43(10): 1939. CrossRef - Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis
C. Demtröder, W. Solass, J. Zieren, D. Strumberg, U. Giger‐Pabst, M.‐A. Reymond
Colorectal Disease.2016; 18(4): 364. CrossRef - Therapeutic options for peritoneal metastasis arising from colorectal cancer
Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso
World Journal of Gastrointestinal Pharmacology and Therapeutics.2016; 7(3): 343. CrossRef - Challenges in the multidisciplinary management of stage IV colon and rectal cancer
Pompiliu Piso, Dirk Arnold, Gabriel Glockzin
Expert Review of Gastroenterology & Hepatology.2015; 9(3): 317. CrossRef - Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis
Gabriel Glockzin, Michael Gerken, Sven A Lang, Monika Klinkhammer-Schalke, Pompiliu Piso, Hans J Schlitt
BMC Cancer.2014;[Epub] CrossRef - Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
H. Ishida, K. Kumamoto, K. Ishibashi, S. Hatano, T. Matsuzawa, N. Okada, Y. Kumagai, H. Baba, N. Haga
Techniques in Coloproctology.2013; 17(6): 647. CrossRef - Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?
E. Chouillard, V. Greco, N. Tsiminikakis
Techniques in Coloproctology.2013; 17(6): 619. CrossRef - Peritoneal carcinomatosis from colorectal cancer: hyperthermic intraperitoneal chemotherapy and the role of systemic chemotherapy
Michael Michael
Colorectal Cancer.2013; 2(5): 449. CrossRef - Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer
Jan Franko, Charles D. Goldman, Kiran K. Turaga
Current Colorectal Cancer Reports.2013; 9(3): 242. CrossRef - A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial
Gabriel Glockzin, Justine Rochon, Dirk Arnold, Sven A Lang, Frank Klebl, Florian Zeman, Michael Koller, Hans J Schlitt, Pompiliu Piso
BMC Cancer.2013;[Epub] CrossRef - A Long Survived Case of Transverse Colon Cancer with Peritoneal Dissemination Treated by Multidisciplinary Treatment Including Hyperthermic Intraperitoneal Chemotherapy
Toshiyuki Nakazawa, Takanori Goi, Mituhiro Morikawa, Kenji Koneri, Makoto Murakami, Yasuo Hirono, Atushi Iida, Kanji Katayama, Akio Yamaguchi, Atomu Murai
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons).2012; 37(6): 1136. CrossRef
- Results of complete cytoreductive strategy in patients with peritoneal metastases of colorectal origin with or without extraperitoneal metastases: A bicentric analysis
- 11,944 View
- 63 Download
- 15 Crossref
- Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection
- Ji Hyun Lee, Min-Chan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Sung-Hyun Kim, Kyung A Kwon, Suee Lee, Jin Sook Jeong, Seok-Reyol Choi, Hyo-Jin Kim
- Cancer Res Treat. 2011;43(2):117-123. Published online June 30, 2011
- DOI: https://doi.org/10.4143/crt.2011.43.2.117
-
Abstract
PDFPubReaderePub
- PURPOSE
To assess the usefulness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy.
MATERIALS AND METHODS
Sixty-two patients underwent curative surgical resection between January, 2006 and December, 2008. Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49 had successful assay results and they received either oral 5-fluorouracil or other chemotherapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-fluorouracil and whose assays were successful.
RESULTS
The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years (range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-group showed a significantly longer time to relapse (not reached in the sensitive-group vs. 24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group, p=0.16, statistically insignificant).
CONCLUSION
Patients who receive curative surgical resection significantly benefit from sensitive adjuvant chemotherapy according to ATP-CRA results for time to relapse. -
Citations
Citations to this article as recorded by- In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
Cancer Research and Treatment.2016; 48(3): 970. CrossRef - Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
Sang Hun Jung, So Hyun Kim, Jae Hwang Kim
Korean Journal of Clinical Oncology.2015; 11(2): 51. CrossRef - Purinergic signalling in the gastrointestinal tract and related organs in health and disease
Geoffrey Burnstock
Purinergic Signalling.2014; 10(1): 3. CrossRef - Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes
KOJI HARADA, TARANNUM FERDOUS, YOSHIYA UEYAMA
International Journal of Oncology.2014; 44(4): 1302. CrossRef - Purinergic signalling and cancer
Geoffrey Burnstock, Francesco Di Virgilio
Purinergic Signalling.2013; 9(4): 491. CrossRef - Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines
KAZUYA UCHIBORI, ATSUSHI KASAMATSU, MASAHIKO SUNAGA, SATOSHI YOKOTA, TOMOYA SAKURADA, ERIKO KOBAYASHI, MASAHARU YOSHIKAWA, KATSUHIRO UZAWA, SHIRO UEDA, HIDEKI TANZAWA, NOBUNORI SATO
International Journal of Oncology.2012; 40(4): 1005. CrossRef
- In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
- 11,667 View
- 46 Download
- 6 Crossref
Case Report
- A Case of 5-Fluorouracil Induced Encephalopathy
- Kyung A Kwon, Hyuk-Chan Kwon, Min Chan Kim, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hyo-Jin Kim
- Cancer Res Treat. 2010;42(2):118-120. Published online June 30, 2010
- DOI: https://doi.org/10.4143/crt.2010.42.2.118
-
Abstract
PDFPubReaderePub
Patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at risk for experiencing serious adverse effects following 5-fluorouracil (5-FU) based chemotherapy. Neurotoxicity is considered an extremely rare side effect of 5-FU. We report here on an unusual case of 5-FU induced encephalopathy. A 38-year-old woman with advanced gastric carcinoma was treated with adjuvant chemotherapy that consisted of infused 5-FU (1,000 mg/m2) for 5 days and cisplatin (60 mg/m2) on day 1 following total gastrectomy. Nineteen days after starting chemotherapy, the patient displayed a sudden onset of slurred speech, confusion, cognitive disturbances and paranoia. A magnetic resonance image (MRI) of the brain showed no structural abnormalities, and the other laboratory tests provided no explanations for her symptoms, other than a slightly elevated ammonia level. The patient was treated with a lactulose retention enema and thiamine infusion, the 5-FU was halted and her symptoms then recovered after 7 days.
-
Citations
Citations to this article as recorded by- Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
Ana Dias-Carvalho, Mariana Ferreira, Rita Ferreira, Maria de Lourdes Bastos, Susana Isabel Sá, João Paulo Capela, Félix Carvalho, Vera Marisa Costa
Archives of Toxicology.2022; 96(1): 11. CrossRef - Chemotherapy-Induced Acute Reversible Toxic Leukoencephalopathy
A. K. Vishnu, Thara Pratap, Dhanya Jacob, Muhammed Jasim Abdul Jalal, Anupama Gopalakrishnabhakthan
Current Medical Issues.2022; 20(3): 194. CrossRef - Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation
Hemnishil K. Marella, Rahul Peravali, Amit L. Jain, Satheesh Nair, Benedict Maliakkal, Uchenna Agbim, Rajanshu Verma
Baylor University Medical Center Proceedings.2020; 33(2): 256. CrossRef - Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Claudia Pellacani, Georgios Eleftheriou
Advances in Medical Sciences.2020; 65(2): 265. CrossRef - Thiamine deficiency in the outpatient psychiatric oncology setting: A case series
Rose Zhang, Sudhakar Tummala, Deepti Chopra
Palliative and Supportive Care.2020; 18(5): 609. CrossRef - 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy
Alice Boilève, Camille Wicker, Benjamin Verret, Florence Leroy, David Malka, Mathieu Jozwiak, Clément Pontoizeau, Chris Ottolenghi, Pascale De Lonlay, Michel Ducreux, Antoine Hollebecque
Anti-Cancer Drugs.2019; 30(3): 313. CrossRef - An imaging-based review of systemic therapies and associated toxicities in metastatic pancreatic cancer as per the 2018 ASCO guidelines: what every radiologist should know
Daniel A. Smith, Bhanusupriya Somarouthu, Nikhil H. Ramaiya
Abdominal Radiology.2019; 44(6): 2182. CrossRef - A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole
Tatsuya Fukumoto, Fumiaki Katada, Susumu Sato, Hidehiro Shibayama, Shigeo Murayama, Toshio Fukutake
Rinsho Shinkeigaku.2018; 58(2): 118. CrossRef - The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate
Cynthia Santos, Brent W. Morgan, Robert J. Geller
The American Journal of Emergency Medicine.2017; 35(5): 802.e7. CrossRef - Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, Véronique Guerin-Meyer, Oana Cojocarasu, Ce
Seminars in Oncology.2017; 44(1): 13. CrossRef - Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy
Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Keiji Sugiyama, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Yozo Sato, Hidekazu Yamaura, Yoshitaka Inaba, Makoto Ishihara, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
Medicine.2017; 96(22): e6874. CrossRef - Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy
May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti
The American Journal of Emergency Medicine.2017; 35(9): 1389. CrossRef - Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology
Yuichiro Kitai, Takeshi Matsubara, Taro Funakoshi, Takahiro Horimatsu, Manabu Muto, Motoko Yanagita
Renal Replacement Therapy.2016;[Epub] CrossRef - Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer
Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Abdülsamet Erden
Journal of Oncology Pharmacy Practice.2015; 21(1): 72. CrossRef - Subacute reversible toxic encephalopathy related to treatment with capecitabine: A case report with literature review and discussion of pathophysiology
E. Lyros, S. Walter, I. Keller, P. Papanagiotou, K. Fassbender
NeuroToxicology.2014; 42: 8. CrossRef - Epilepsy in women with gynecologic malignancies
Yixue Gu, Qin Yang, Xuefeng Wang
Expert Review of Neurotherapeutics.2014; 14(5): 503. CrossRef - Posterior Reversible Encephalopathy Syndrome (PRES) After Treatment With Oxaliplatin and 5-Fluorouracil
Nicholas Truman, Daniel Nethercott
Clinical Colorectal Cancer.2013; 12(1): 70. CrossRef - 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases
Pierre-Yves Cordier, André Nau, Joseph Ciccolini, Manuela Oliver, Cédric Mercier, Bruno Lacarelle, Eric Peytel
Cancer Chemotherapy and Pharmacology.2011; 68(3): 823. CrossRef
- Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
- 11,488 View
- 97 Download
- 18 Crossref
Original Articles
- Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer
- Jung Hwan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Suee Lee, Sung-Hyun Kim, Dae-Cheol Kim, Jin-Hwa Lee, Hyung-Sik Lee, Se-Heun Cho, Hyo-Jin Kim
- Cancer Res Treat. 2008;40(3):101-105. Published online September 30, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.3.101
-
Abstract
PDFPubReaderePub
Purpose Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane.
Materials and Methods We evaluated the use of a GP regimen (1,000 mg/m2 gemcitabine administered on days 1 and 8 plus 60 mg/m2 cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.
Results The median patient age was 49 years (age range, 35~69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14~44%). The median time to progression was 5.2 months (95% CI, 3.6~6.8 months). Median survival was 19.5 months (95% CI, 11.2~27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths.
Conclusions Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.
-
Citations
Citations to this article as recorded by- Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
The Korean Journal of Internal Medicine.2021; 36(1): 182. CrossRef - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Jinfeng Zhang, Mingxi Lin, Yizi Jin, Linhan Gu, Ting Li, Baoying Yuan, Biyun Wang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Jian Zhang, Xichun Hu
Breast Cancer Research and Treatment.2020; 182(3): 719. CrossRef - Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
Jung Sun Kim, In Hae Park, Keun Seok Lee, Jungsil Ro
Journal of Breast Cancer.2014; 17(4): 339. CrossRef - A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
Pramod K. Julka, Raju T. Chacko, Shona Nag, Rajinder Parshad, Aravindan Nair, Chaitanyanand B. Koppiker, Fen Chao Richard Xue, Helen Barraclough, Navreet Dhindsa, Anil Seth, Anurita Majumdar, Tarun Puri
Breast Cancer.2013; 20(4): 357. CrossRef - Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer
Tao Wang, Shaohua Zhang, Min Zeng, Xinyou Lu, Ge Shen, Shikai Wu, Santai Song, Zefei Jiang
Medical Oncology.2012; 29(1): 56. CrossRef - Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H J Stemmler, D diGioia, W Freier, H W Tessen, G Gitsch, W Jonat, W Brugger, E Kettner, W Abenhardt, H Tesch, H J Hurtz, S Rösel, O Brudler, V Heinemann
British Journal of Cancer.2011; 104(7): 1071. CrossRef - Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Ali I. Shamseddine, Fadi S. Farhat
Chemotherapy.2011; 57(6): 468. CrossRef - Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
Binghe Xu, Zefei Jiang, Sung-Bae Kim, Shiying Yu, Jifeng Feng, Artur Malzyner, Auro del Giglio, Hyun C. Chung, Li Jun Shen, Daniel Lee Kay Pen
Breast Cancer.2011; 18(3): 203. CrossRef
- Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
- 10,828 View
- 68 Download
- 8 Crossref
- Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis
- Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim
- Cancer Res Treat. 2008;40(1):22-26. Published online March 31, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.1.22
-
Abstract
PDFPubReaderePub
Purpose Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined with cisplatin to determine the treatment outcomes for patients with locally advanced or metastatic pancreatic cancer.
Materials and Methods From 2001 to 2007, we enrolled 60 patients who were treated with gemcitabine or gemcitabine combined with cisplatin for locally advanced or metastatic pancreatic cancer. Gemcitabine 1, 000 mg/m2 (G) was administrated at day 1 and day 8 every 3 weeks. Cisplatin 60 mg/m2 was added at day 1 every 3 weeks to the gemcitabine schedule (GP).
Results Number of G: GP was 34: 26, locally advanced to metastatic ratio was 35% to 65% in group G and 46% to 54% in group GP. Median follow up duration was 29 months. The median number of chemotherapy cycles was 4 (range: 2~11) for the G group, and 4 (range: 1~11) for the GP group. The response rate of the G and GP groups was 17% and 11%, respectively. The progression free survival (PFS) was 4.5 months and 2.8 months, respectively, for the G and GP groups. The overall survival (OS) was 10.7 and 8.7 months respectively, for the G and GP groups, but there is no statistically significant difference of the PFS (p=0.2396) and OS (p=0.4643) between the 2 groups. The hematological toxicity profile was similar (the grade III neutropenia and thrombocytopenia was 4.4% and 3.1%, respectively, in G group, and 7.5% and 2.8%, respectively, in the GP group). But non-hematological toxicities such as skin rash, abnormal liver function and nausea/vomiting were observed in 3 patients of the GP group. On the prognostic factor analysis, no factors predicted a longer PFS and OS for both the G and GP groups.
Conclusions Gemcitabine single treatment might be more tolerable and it had the same efficacy compared to cisplatin combination treatment in this retrospective study.
-
Citations
Citations to this article as recorded by- Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
David J. Kuter
Haematologica.2022; 107(6): 1243. CrossRef - Treatment of drug-induced immune thrombocytopenias
Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul
Haematologica.2022; 107(6): 1264. CrossRef - Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
Giuseppe Belfiore, Maria Paola Belfiore, Alfonso Reginelli, Raffaella Capasso, Francesco Romano, Giovanni Pietro Ianniello, Salvatore Cappabianca, Luca Brunese
Medical Oncology.2017;[Epub] CrossRef - Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Forget
International Journal of Hematology.2017; 106(6): 765. CrossRef - Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam, Yasser Mostafa Kamel
Cancer Medicine.2015; 4(1): 16. CrossRef - Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer
Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao
Clinical Therapeutics.2014; 36(7): 1054. CrossRef - Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
PLoS ONE.2014; 9(8): e104346. CrossRef - Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Samantha B. Kasloff, Matteo S. Pizzuto, Micol Silic-Benussi, Silvia Pavone, Vincenzo Ciminale, Ilaria Capua, K. L. Beemon
Journal of Virology.2014; 88(16): 9321. CrossRef - Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
Wenbo Zhu, Jingjie Li, Sihan Wu, Shifeng Li, Liang Le, Xingwen Su, Pengxin Qiu, Haiyan Hu, Guangmei Yan
Pancreas.2012; 41(7): 1029. CrossRef
- Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
- 11,539 View
- 57 Download
- 9 Crossref
Case Reports
- Unusual Presentation of Large B Cell Lymphoma- Bone and Stomach- Treated with Autologous Transplantation
- Bokyung Kim, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Sook Hee Hong, Sung-Soo Kim, Hyo-Jin Kim
- Cancer Res Treat. 2007;39(4):181-184. Published online December 31, 2007
- DOI: https://doi.org/10.4143/crt.2007.39.4.181
-
Abstract
PDFPubReaderePub
Extranodal presentation of diffuse large B cell lymphoma (DLBL) is frequently observed in the gastrointestinal tract, CNS, bone, testes and liver. However, the simultaneous detection of multiple extranodal involvement at presentation is quite an uncommon occurrence. In this study, we report on a patient with an uncommon presentation of DLBL, and he had symptoms of left knee joint pain and hematemesis, characterized by bone and stomach involvement. Computed tomography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning revealed a rapid, extensive spread to the bones and soft tissues. Subsequent histopathological examination verified the bony and gastric CD20-positive DLBL localization. We diagnosed this case as DLBL of stage IV with an international prognostic index of 3, and classified him into the high intermediate risk group. This patient was treated via chemotherapy with an R-CHOP regimen. After achieving a partial response, the patient received autologous peripheral blood stem cell transplantation. The patient attained partial remission, as shown on the FDG-PET scan, and he displayed improvement of his left femur pain.
- 9,246 View
- 50 Download
- Extraskeletal Mesenchymal Chondrosarcoma of the Heart Responded to Systemic Chemotherapy: A Case Report
- Chien Ter Hsing, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Tae-Ho Park, Jong Soo Woo, Seo Hee Na, Hyo-Jin Kim
- Cancer Res Treat. 2007;39(3):131-133. Published online September 30, 2007
- DOI: https://doi.org/10.4143/crt.2007.39.3.131
-
Abstract
PDFPubReaderePub
Mesenchymal chondrosarcoma is a rare cartilaginous ne - oplasm of an extraskeletal origin, and this predominately occurs in the head and neck, and also in the lower extremities. Fewer than twenty cases of cardiac mesenchymal chondrosarcoma have so far been reported on. For the most part, the results of treatment for patients with this condition have been dismal. In this study, we describe a case of cardiac mesenchymal chondrosarcoma that responded to chemotherapy following surgical biopsy. A 46-year-old man was referred for evaluation of his pleural effusions in both lungs. Chest computed tomography revealed an ovoid-shaped mass in the posterior wall of the patient's left atrium. The echocardiogram revealed a large ovoid-shaped immobile mass (11×6 cm2) in the pericardiac space, which was attached to the posterior wall of the left atrium. Emergency pericardiostomy with closure thoracostomy was performed. Seven days later, a thoracotomy was performed for reduction and diagnosis of the cardiac mass. The pathological diagnosis was extraskeletal mesenchymal chondrosarcoma of the heart.. Postoperative chemotherapy was performed for the huge remaining mass with a combined regimen of etoposide, ifosfamide and cisplatin. After 6 cycles, the patient showed a partial response without symptoms. Although cardiac mesenchymal chondrosarcoma has been reported to be chemotherapy-resistant with a short survival duration, chemotherapy may prove to be an effective treatment modality.
-
Citations
Citations to this article as recorded by- Unusual Presentation of Extraskeletal Mesenchymal Chondrosarcoma: A Case Report
Mathilde Bernard, Ramy Samargandi
Cureus.2023;[Epub] CrossRef - Mesenchymal chondrosarcoma: imaging features and clinical findings
Soleen Ghafoor, Meera R. Hameed, William D. Tap, Sinchun Hwang
Skeletal Radiology.2021; 50(2): 333. CrossRef - 18F-FDG PET/CT Findings of Mesenchymal Chondrosarcoma of the Orbit
Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
Clinical Nuclear Medicine.2018; 43(2): e43. CrossRef - Mesenchymal chondrosarcoma of the orbit: imaging features of CT and MRI
Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
The British Journal of Radiology.2018; 91(1090): 20170579. CrossRef - Radiofrequency ablation of metastatic chondrosarcoma-associated refractory ventricular tachycardia originating from the right ventricular outflow tract: A case report and literature review
Xiangmin Shi, Zhuo Liang, Jian Li, Jianping Guo, Zhaoliang Shan, Yutang Wang
Experimental and Therapeutic Medicine.2016; 12(3): 1803. CrossRef - A Rare Case of Extraskeletal Mesenchymal Chondrosarcoma with Dedifferentiation Arising from the Buccal Space in a Young Male
Shalini R. Gupta, Ravinder K. Saran, Pankaj Sharma, Aadithya B. Urs
Journal of Maxillofacial and Oral Surgery.2015; 14(S1): 293. CrossRef - Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years
Jie Xu, Dasen Li, Lu Xie, Shun Tang, Wei Guo, David M Loeb
PLOS ONE.2015; 10(4): e0122216. CrossRef - A fatal case of primary cardiac chondrosarcoma presenting with amaurosis fugax
Jens Sundbøll, Nils Henrik Stubkjær Hansson, Steen Baerentzen, Manan Pareek
BMJ Case Reports.2015; : bcr2015212178. CrossRef - Extraskeletal Intraspinal Mesenchymal Chondrosarcoma; 18F-FDG PET/CT Finding
EunSeong Lee, Ho Young Lee, Gheeyoung Choe, Ki-Jeong Kim, Won Woo Lee, Sang Eun Kim
Clinical Nuclear Medicine.2014; 39(1): e64. CrossRef - Management of renal extraskeletal mesenchymal chondrosarcoma
Vitalie Gherman, Ciprian Tomuleasa, Catalina Bungardean, Nicolae Crisan, Victor-Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman
BMC Surgery.2014;[Epub] CrossRef - Primary Cardiac Chondrosarcoma
Guofei Zhang, Xiaofan Chen, Lei Guo, Qiang Feng, Yiming Ni
Journal of Cardiac Surgery.2012; 27(2): 186. CrossRef
- Unusual Presentation of Extraskeletal Mesenchymal Chondrosarcoma: A Case Report
- 9,662 View
- 52 Download
- 11 Crossref
Original Article
- A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
- Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
- Cancer Res Treat. 2007;39(1):6-9. Published online March 31, 2007
- DOI: https://doi.org/10.4143/crt.2007.39.1.6
-
Abstract
PDFPubReaderePub
Purpose To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.
Materials and Methods Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.
Results 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).
Conclusion The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.
-
Citations
Citations to this article as recorded by- Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
Cancer Management and Research.2022; Volume 14: 2825. CrossRef - Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
Japanese Journal of Clinical Oncology.2009; 39(4): 237. CrossRef
- Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
- 9,338 View
- 45 Download
- 2 Crossref
First
Prev
